Atrion Corporation (ATRI) Holdings Raised by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lifted its position in Atrion Corporation (NASDAQ:ATRI) by 1.9% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 63,268 shares of the medical instruments supplier’s stock after purchasing an additional 1,151 shares during the quarter. Dimensional Fund Advisors LP owned 3.45% of Atrion Corporation worth $40,700,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Capital Analysts LLC purchased a new stake in Atrion Corporation during the 2nd quarter valued at about $434,000. Neuberger Berman Group LLC raised its position in Atrion Corporation by 7.4% during the 2nd quarter. Neuberger Berman Group LLC now owns 82,894 shares of the medical instruments supplier’s stock valued at $53,326,000 after purchasing an additional 5,695 shares during the last quarter. Renaissance Technologies LLC raised its position in Atrion Corporation by 46.3% during the 2nd quarter. Renaissance Technologies LLC now owns 58,834 shares of the medical instruments supplier’s stock valued at $37,848,000 after purchasing an additional 18,633 shares during the last quarter. Ameriprise Financial Inc. raised its position in Atrion Corporation by 600.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 3,383 shares of the medical instruments supplier’s stock valued at $2,177,000 after purchasing an additional 2,900 shares during the last quarter. Finally, Schroder Investment Management Group raised its position in Atrion Corporation by 35.9% during the 2nd quarter. Schroder Investment Management Group now owns 851 shares of the medical instruments supplier’s stock valued at $544,000 after purchasing an additional 225 shares during the last quarter. Hedge funds and other institutional investors own 59.62% of the company’s stock.

WARNING: This story was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2017/11/11/dimensional-fund-advisors-lp-grows-holdings-in-atrion-corporation-atri.html.

In related news, Chairman Emile A. Battat sold 1,408 shares of the firm’s stock in a transaction that occurred on Wednesday, September 6th. The stock was sold at an average price of $652.91, for a total transaction of $919,297.28. Following the completion of the transaction, the chairman now owns 148,881 shares of the company’s stock, valued at approximately $97,205,893.71. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 23.10% of the stock is owned by company insiders.

Shares of Atrion Corporation (ATRI) traded down $11.50 during trading hours on Friday, hitting $633.55. The stock had a trading volume of 4,500 shares, compared to its average volume of 5,503. Atrion Corporation has a 12-month low of $433.95 and a 12-month high of $694.00. The company has a market cap of $1,160.00, a price-to-earnings ratio of 38.33 and a beta of 0.86.

Atrion Corporation (NASDAQ:ATRI) last announced its earnings results on Wednesday, November 8th. The medical instruments supplier reported $4.29 earnings per share (EPS) for the quarter. Atrion Corporation had a return on equity of 18.34% and a net margin of 22.98%. The firm had revenue of $37.90 million during the quarter.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Friday, December 1st will be given a dividend of $1.20 per share. This represents a $4.80 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date is Thursday, November 30th. Atrion Corporation’s dividend payout ratio (DPR) is presently 26.59%.

Separately, BidaskClub lowered Atrion Corporation from a “strong-buy” rating to a “buy” rating in a research report on Thursday, July 27th.

Atrion Corporation Profile

Atrion Corporation (Atrion) is engaged in developing and manufacturing products, primarily for medical applications. The Company’s medical products range from fluid delivery devices to ophthalmic and cardiovascular products. Its fluid delivery products include valves that promote infection control and needle safety.

Institutional Ownership by Quarter for Atrion Corporation (NASDAQ:ATRI)

Receive News & Ratings for Atrion Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply